Ascendis Pharma A/S (NASDAQ:ASND) Stake Lessened by First Turn Management LLC

First Turn Management LLC cut its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 19.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 150,593 shares of the biotechnology company's stock after selling 35,988 shares during the quarter. Ascendis Pharma A/S comprises about 3.6% of First Turn Management LLC's holdings, making the stock its 8th largest position. First Turn Management LLC owned about 0.25% of Ascendis Pharma A/S worth $22,485,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Thrivent Financial for Lutherans raised its stake in shares of Ascendis Pharma A/S by 0.3% during the 3rd quarter. Thrivent Financial for Lutherans now owns 78,473 shares of the biotechnology company's stock valued at $11,717,000 after purchasing an additional 228 shares during the period. Sivik Global Healthcare LLC purchased a new position in Ascendis Pharma A/S in the third quarter worth $1,493,000. Oppenheimer Asset Management Inc. increased its stake in Ascendis Pharma A/S by 10.0% in the third quarter. Oppenheimer Asset Management Inc. now owns 7,622 shares of the biotechnology company's stock valued at $1,138,000 after acquiring an additional 695 shares during the last quarter. Crossmark Global Holdings Inc. purchased a new position in shares of Ascendis Pharma A/S during the 3rd quarter valued at about $1,212,000. Finally, Assetmark Inc. purchased a new position in shares of Ascendis Pharma A/S during the 3rd quarter valued at about $331,000.

Ascendis Pharma A/S Price Performance

ASND stock traded up $2.44 on Tuesday, reaching $124.44. 621,763 shares of the company traded hands, compared to its average volume of 451,616. The firm has a fifty day simple moving average of $132.59 and a 200-day simple moving average of $132.38. The company has a market cap of $7.55 billion, a P/E ratio of -15.40 and a beta of 0.66. Ascendis Pharma A/S has a one year low of $90.13 and a one year high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The company had revenue of $38.75 million for the quarter, compared to the consensus estimate of $94.74 million. On average, sell-side analysts forecast that Ascendis Pharma A/S will post -7.3 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Cantor Fitzgerald reiterated an "overweight" rating and set a $170.00 price target on shares of Ascendis Pharma A/S in a research report on Friday. Wells Fargo & Company lifted their price objective on Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an "overweight" rating in a report on Tuesday, September 17th. TD Cowen lowered their price target on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a "buy" rating for the company in a report on Friday. Stifel Nicolaus upped their price target on Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a "buy" rating in a research report on Friday. Finally, Citigroup upped their price objective on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a "buy" rating in a report on Tuesday, September 17th. One analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $191.77.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.